Khan Madiha, Wallace Carly E, Ahmed Fahad, Rahman Syed Minhaj, Memon Nashwah, Haque Adel
New York Institute of Technology College of Osteopathic Medicine, Old Westbury, NY, USA.
Lake Erie College of Osteopathic Medicine, Bradenton, FL, USA.
J Psoriasis Psoriatic Arthritis. 2024 Apr;9(2):61-68. doi: 10.1177/24755303231217491. Epub 2023 Nov 18.
Despite recent advances in biologics, there is a lack of significant evidence regarding the comparative efficacy of biologics in treating more resistant features of psoriasis, namely nail psoriasis. A systematic review synthesizing data from multiple studies is efficacious in assessing the comparative efficacy among biologics for the treatment of nail psoriasis.
To evaluate and compare the efficacy of biologics for the treatment of nail psoriasis.
Utilizing PRISMA guidelines, a systematic literature review was conducted using the Pubmed database on November 16, 2022. Studies selected were phase 3 or 4 randomized clinical trials, clinical studies, or other randomized trials with data on the treatment with biologics for adults with nail psoriasis.
Sixteen studies meeting inclusion criteria were included for analysis. At 24 weeks, the highest mean NAPSI percent improvement achieved at week 24 was by brodalumab (76.9%) followed by etanercept (74%) and ixekizumab (70.5%) while the biologics achieving the greatest proportion of NAPSI 0 were adalimumab (44.6%) and ixekizumab (41%).
This study helps elucidate the comparative efficacy of biologics for the treatment of nail psoriasis. This review suggests that brodalumab and etanercept are associated with the highest percent improvement in nail psoriasis while adalimumab and ixekizumab are associated with the greatest probability of complete nail resolution.
尽管生物制剂最近取得了进展，但关于生物制剂在治疗银屑病更具抗性的特征（即甲银屑病）方面的比较疗效，仍缺乏重要证据。综合多项研究数据的系统评价对于评估生物制剂治疗甲银屑病的比较疗效是有效的。
评估和比较生物制剂治疗甲银屑病的疗效。
利用PRISMA指南，于2022年11月16日在PubMed数据库上进行了系统的文献综述。所选研究为3期或4期随机临床试验、临床研究或其他有生物制剂治疗成人甲银屑病数据的随机试验。
纳入16项符合纳入标准的研究进行分析。在24周时，24周时平均NAPSI改善百分比最高的是布罗达单抗（76.9%），其次是依那西普（74%）和司库奇尤单抗（70.5%），而达到NAPSI 0比例最高的生物制剂是阿达木单抗（44.6%）和司库奇尤单抗（41%）。
本研究有助于阐明生物制剂治疗甲银屑病的比较疗效。该综述表明，布罗达单抗和依那西普与甲银屑病的最高改善百分比相关，而阿达木单抗和司库奇尤单抗与指甲完全恢复的最大可能性相关。
